The effect of rectal diclofenac on prevention of pancreatitis after ERCP

Effect of rectal diclofenac on prevention of pancreatitis after ERCP (Endoscopic Retrograde Cholangio_ Pancreatography) in comparison with control group

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191231045969N2

Enrollment

150

Registered

2020-09-30

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis. K85

Interventions

Intervention 1: Intervention group: Patients receiving two diclofenac rectal suppositories 100 mg, one immediately before ERCP and the other immediately after ERCP.The name of the manufacturer of the

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years Ability to sign consent Intact papilla No contraindication for diclofenac Having an ERCP indication

Exclusion criteria

Exclusion criteria: Acute pancreatitis Allergy to diclofenac Sphincterotomy Basic amylase above 200

Design outcomes

Primary

Measure	Time frame
Acute pancreatitis after ERCP. Timepoint: 24 hours after ERCP operation. Method of measurement: Examination and testing of lipase amylase.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Nikkhah

Iran University of Medical Sciences

Nikkhah.m@iums.ac.ir+98 21 8893 7383

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026